Multus' newest serum replacement product, Proliferum®P, is the first commercially available animal component-free (ACF) media formulation for porcine adipose-derived stem cells, developed in under 6 months using AI-powered optimization.

Multus Biotechnology, the leader in cell culture media optimization, announces the launch of Proliferum® P, a next-generation serum replacement specifically engineered for adipose-derived stem cells (ASCs). ASCs are multipotent cells that differentiate into fat, bone, and cartilage, making them valuable for food production, regenerative medicine, and therapeutics. Using Multus' proprietary media optimization platform and deep expertise in cellular growth requirements and ingredient functionality, Proliferum® P represents a breakthrough in both development speed and performance.

"Traditional approaches typically take 2-4 years to develop serum replacements," said Dr. Soraya Padilla, project lead for Proliferum® P. "Using our proprietary media optimization platform, we’ve designed Proliferum® P specifically for porcine adipose-derived stem cells. By combining high-throughput lab automation, AI, and our unique insights in complex ingredient interactions and cell biology, we’ve built a process that not only accelerates the media development process but also customizes it to specific cell types."

Proliferum® P represents the first commercially available animal component-free (ACF) formulation specifically designed for porcine ASCs, delivering performance that matches or exceeds fetal bovine serum(FBS) while maintaining critical stemness characteristics and adipogenic differentiation capacity. The cost-effective formulation offers a reliable, scalable, quality-controlled alternative with significant performance advantages over traditional FBS. While Proliferum® B, Multus' serum replacement designed for fibroblasts, took nine months to develop, Proliferum® P was specifically engineered for adipose-derived stem cells in just six months while optimizing for cost, cell growth, and functional performance, showcasing the platform's capability to deliver optimal formulations for diverse cell types.

"Our platform doesn't just allow us to match industry standards - it ensures we continuously raise the bar," said Cai Linton, Co-founder and CEO of Multus. "With Proliferum® P, we're delivering a superior product to FBS while demonstrating how AI and automation, in the hands of our experienced scientists, can transform biotechnology development timelines."

Multus is offering Proliferum® P for immediate testing and evaluation by companies working with porcine ASCs for the development of food and healthcare products.  

This launch marks the third product release from Multus' optimization platform in six months, demonstrating Multus' mission to accelerate biotechnology innovation by providing high-quality, cost-effective cell culture media solutions that empower faster, more efficient research and development.

‍